Company: TAK
Filing Date: 2025-07-30
Form Type: 6-K
Source: 0001395064-25-000120
Chunk: 1

Company: TAKEDA PHARMACEUTICAL CO LTD
Filing Date: 2025-07-30
Form: 6-K
Chunk 1
---
 |     |    |      |     |                     |         |     |    |      |     |                                                  |         |     |    |       |     |                |        |
| Forecasts for Core financial measures are shown below.                                                 |     |                                                                     |           |     |    |      |     |                       |           |     |    |      |     |                     |         |     |    |      |     |                                                  |         |     |    |       |     |                |        |
|                                                                                                        |     | -Percentage figures represent changes from the previous fiscal year |           |     |    |      |     |                       |           |     |    |      |     |                     |         |     |    |      |     |                                                  |         |     |    |       |     |                |        |
|                                                                                                        |     | Core Revenue                                                        |           |     |    |      |     | Core Operating Profit |           |     |    |      |     | Core EPS            |         |     |    |      |     |                                                  |         |     |    |       |     |                |        |
|                                                                                                        |     | -Million JPY                                                        |           |     | -% |      |     | -Million JPY          |           |     | -% |      |     | -JPY                |         |     |    |      |     |                                                  |         |     |    |       |     |                |        |
| For the Fiscal Year Ending March 31, 2026                                                              |     |                                                                     | 4,530,000 |     |    | -1.1 |     |                       | 1,140,000 |     |    | -1.9 |     |                     |         |     |    |  485 |     |                                                  |         |     |    |       |     |                |        |

(Note) Modifications in forecasts of consolidated operating results from the latest announcement: None

The definition of Core financial measures is stated in “Definition and Explanation of Non-IFRS Measures and U.S. Dollar Convenience Translations” in the Financial Appendix.

Takeda uses change in Core Revenue, Core Operating Profit and Core EPS at Constant Exchange Rate (CER) basis as its Management Guidance. The full year management guidance for the fiscal year ending March 31, 2026 (FY2025) has not been revised from the management guidance announced on May 8, 2025